DoW Rare Cancers Idea Development Award
Defense Health Agency Contracting Activity - DHACA
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 17, 2026
- Amount
- Program total $7.4M
- Closes
- Nov 18, 2026 (in 18 days)
Similar opportunities open now
- DoW Rare Cancers Resource and Community Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses Nov 18, 2026 (in 18 days)
- DoW Bone Marrow Failure, Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses Nov 4, 2026
- DoW Bone Marrow Failure, Investigator-Initiated Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses Nov 4, 2026
- DoW Parkinson’s, Investigator-Initiated Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses Nov 6, 2026
- DoW Reconstructive Transplant, Investigator-Initiated Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses Nov 4, 2026
Classification and identifiers
- Solicitation number
- HT942526RCRPIDA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $7.4M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation. Distinctive Features: The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research. Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study. Research should have high potential impact on rare cancers and the patient community.